How Low Will Pfizer's Dividend Go After the Mylan-Upjohn Deal?

A dividend cut is on the way for one of the biggest drugmakers in the world. But it's not because of the COVID-19 pandemic. It's not because of financial problems at all.

Pfizer (NYSE: PFE) will lower its dividend payout at some point later this year for a straightforward reason. The pharma giant plans to spin off its Upjohn unit and merge it with Mylan (NASDAQ: MYL). The transaction will form a new entity that will be known as Viatris.

But just how low will Pfizer's dividend go after the Mylan-Upjohn deal is finalized?

Continue reading

Source Fool.com